PUBU Ciren1, LIU Jifeng2, BA Luo3
|  Zhou GJ, Xiao M, Zhao LN, et al. MicroRNAs as novel biomarkers for the differentiation of malignant versus benign thyroid lesions: a meta-analysis[J]. Genet Mol Res, 2015, 14(3):7279-7289.
 王宇,马奔. 超声引导下热消融技术尚不适用于甲状腺癌及甲状腺滤泡性肿瘤治疗[J]. 山东大学耳鼻喉眼学报,2016, 30(2):20-22. WANG Yu, MA Ben. Ultrasound guided thermoablation does not fit for thyroid carcinoma and follicular neoplasm[J]. J Otolaryngol Ophthal Shandong Univ,2016, 30(2):20-22.
 Jiang K, Lei J, Chen W, et al. Association of the preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios with lymph node metastasis and recurrence in patients with medullary thyroid carcinoma[J]. Medicine(Baltimore), 2016, 95(40):5079.
 Salazar-Onfray F, Lopez MN, Mendoza-Naranjo A. Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape[J]. Cytokine Growth Factor Rev, 2007, 18(1-2):171-182.
 Dalpiaz O, Pichler M, Mannweiler S, et al. Validation of the pretreatment derived neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma[J]. Br J Cancer, 2014, 110(10):2531-2536.
 Liu CL, Lee JJ, Liu TP, et al. Blood neutrophil-to-lymphocyte ratio correlates with tumor size in patients with differentiated thyroid cancer[J]. J Surg Oncol, 2013, 107(5):493-497.
 Wenger FA, Jacobi CA, Zieren J, et al. Tumor size and lymph-node status in pancreatic carcinoma- is there a correlation to the preoperative immune function?[J]. Lang Arch Surg, 1999, 384(5):473-478.
 Guarino V, Castellone MD, Avilla E, et al. Thyroid cancer and inflammation[J]. Mol Cell Endocrinol, 2010, 321(1):94-102.
 Larson SD, Jackson LN, Riall TS, et al. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway[J]. J Am Coll Surg, 2007, 204(5):764-773.
 Bradly DP, Reddy V, Prinz RA, et al. Incidental papillary carcinoma in patients treated surgically for benign thyroid diseases[J]. Surgery, 2009, 146(6):1099-1104.
 Proctor MJ, McMillan DC, Morrison DS, et al. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer[J]. Br J Cancer, 2012, 107(4):695-699.
 Clarke SJ, Chua W, Moore M, et al. Use of inflammatory markers to guide cancer treatment[J]. Clin Pharmacol Ther, 2011, 90(3):475-478.
 Seretis C, Gourgiotis S, Gemenetzis G, et al. The significance of neutrophil/lymphocyte ratio as a possible marker of underlying papillary microcarcinomas in thyroidal goiters: a pilot study[J]. Am J Surg, 2013, 205(6):691-696.
 Kim JY, Park T, Jeong SH, et al. Prognostic importance of baseline neutrophil to lymphocyte ratio in patients with advanced papillary thyroid carcinomas[J]. Endocrine, 2014, 46(3): 526-531.
 Kocer D, Karakukcu C, Karaman H, et al. May the neutrophil/lymphocyte ratio be a predictor in the differentiation of different thyroid disorders?[J]. Asian Pac J Cancer Prev, 2015, 16(9):3875-3879.
 Liu J, Du J, Fan J, et al. The Neutrophil-to-lymphocyte ratio correlates with age in patients with papillary thyroid carcinoma[J]. ORL J Otorhinolaryngol Relat Spec, 2015, 77(2):109-116.
 Kim SM, Kim EH, Kim BH, et al. Association of the preoperative neutrophil-to-ymphocyte count ratio and platelet-to-lymphocyte count ratio with clinicopathological characteristics in patients with papillary thyroid cancer[J]. Endoc Metab(Seoul), 2015, 30(4): 494-501.
 Liu JF, Ba L, Lv H, et al. Association between neutrophil-to-lymphocyte ratio and differentiated thyroid cancer: a meta-analysis[J]. Sci Rep, 2016, 6:38551.
 Cho JS, Park MH, Ryu YJ, et al. The neutrophil to lymphocyte ratio can discriminate anaplastic thyroid cancer against poorly or well differentiated cancer[J]. Ann Surg Treat Res, 2015, 88(4):187-192.
 Gu XB, Tian T, Tian XJ, et al. Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis[J]. Sci Rep, 2015, 5:12493.
 Lang BH, Ng CP, Au KB, et al. Does preoperative neutrophil lymphocyte ratio predict risk of recurrence and occult central nodal metastasis in papillary thyroid carcinoma?[J]. World J Surg, 2014, 38(10):2605-2612.
 Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer[J]. Future Oncol, 2010, 6(1):149-163.
 Yaylaci S, Tosun O, Sahin O, et al. Lack of variation in inflammatory hematological parameters between benign nodular goiter and papillary thyroid cancer[J]. Asian Pac J Cancer Prev, 2016, 17(4):2321-2323.
 Sun C, Li Q, Hu Z, et al. Treatment and prognosis of anaplastic thyroid carcinoma: experience from a single institution in China[J]. PLoS One, 2013, 8(11):e80011.
 Ahmed SR, Ball DW. Clinical review: Incidentally discovered medullary thyroid cancer: diagnostic strategies and treatment[J]. J Clin Endocrinol Metab, 2011, 96(5):1237-1245.
 Guo YZ, Pan L, Du CJ, et al. Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies[J]. Asian Pac J Cancer Pre, 2013, 14(1):243-248.
 Hou X, Jiang L, Chen C, et al. Different expression of erythrocyte sedimentation rate and c-reactive protein in papillary thyroid carcinoma and nodular goiter[J]. Clin Lab, 2015, 61(7):793-799.
 Stanciu AE, Serdarevic N, Hurduc AE, et al. IL-4,IL-10 and high sensitivity-CRP as potential serum biomarkers of persistent/recurrent disease in papillary thyroid carcinoma with/without Hashimotos thyroiditis[J]. Scand J Clin Lab Invest, 2015, 75(7):539-548.
|||QIU Jie, SUN Shasha, SUN Yan. Interpretation of the eighth edition of thyroid cancer tumor-node-metastasis staging by American Joint Committee on Cancer. [J]. J Otolaryngol Ophthalmol Shandong Univ, 2017, 31(6): 5-8.|
|||YU Jichun. Neck dissection to differentiated thyroid carcinoma. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(2): 10-12.|
|||ZHUANG Da-yong, HE Qing-qing, FAN Zi-yi, ZHENG Lu-ming, ZHU Jian, ZHOU Peng, DUAN Song-jian, YUE Tao, DONG Xue-feng. Intra-operative nerve monitoring in re-operation for differentiated thyroid carcinoma [J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(6): 5-8.|
|||ZHAO Guo-wei， HE Qing-qing， ZHUANG Da-yong， ZHENG Lu-ming， FAN Zi-yi， ZHU Jian， YU Fang， ZHOU Peng， HOU Lei， JIANG Hui-ping. Benefits and risks of I-131 therapy in patients with differentiated thyroid cancer [J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(6): 16-21.|
|||CAO Lei， HE Qing-qing， ZHUANG Da-yong， ZHENG Lu-ming， FAN Zi-yi, ZHOU Peng， ZHU Jian. Low small incision in total thyroidectomy and selective neck lymphnode dissection [J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(2): 56-59.|
|||SUN Zhen-feng, ZHANG Jia, XU Hong-ming, WANG Guo, DONG Pin. Diagnosis and treatment of micro-thyroid cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2012, 26(1): 44-45.|